Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EXCRETION Clear all

Conditions: Generalized Anxiety Disorder
Interventions: PD 0332334; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer
Interventions: DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects (HS)
Interventions: zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetic Foot Ulcer
Interventions: Noveon laser; Device
Lead sponsor: Nomir Medical Technologies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Healthy Volunteers, Healthy
Interventions: GC4419; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: LY3009104; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]-LY3866288, LY3866288; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]-plazomicin; Drug
Lead sponsor: Achaogen, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: KBP-5074; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Mitral Regurgitation, Heart Disease
Interventions: Mitral Valve Replacement; Device
Lead sponsor: InnovHeart; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Thousand Oaks, California + 2 more

Conditions: Healthy Volunteer
Interventions: Period 1 treatment, Period 2 treatment; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Fecal Incontinence
Interventions: The Leva Pelvic Health System; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Nocturnal Enuresis, Voiding Dysfunction
Interventions: Nightly Timed Awakening; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 6 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Urinary Incontinence
Interventions: PureWick System, UltraFlex Self-Adhering Male External Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 15
States / cities: Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Healthy
Interventions: Not listed
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Healthy
Interventions: [14C]-PD-0332991; Radiation
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Maintenance of Recommended Sodium Intake
Interventions: Behavior and lifestyle counseling; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 105 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Toxicity;Chemical
Interventions: HOPO 14-1; Drug
Lead sponsor: SRI International; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Plymouth, Michigan

Conditions: IgA Nephropathy (IgAN)
Interventions: Low inflammation diet intervention; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Crohn's Disease
Interventions: Elimination Diet, Dietary Guidelines for Americans; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: TBPM-PI-HBr; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Urinary Incontinence
Interventions: Instructional DVD, Bladder Health Class; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 55 Years and older · Female only
Enrollment: 647 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Philadelphia, Pennsylvania

Conditions: Marijuana Abuse
Interventions: AEF0117; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cancer
Interventions: Sauna (steam); Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

Bioburden Reduction of Diabetic Foot Ulcer

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

A Study of [14C]-LY3866288 in Healthy Participants

A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin

Mass Balance Study of KBP-5074 in Healthy Male Subjects

Reduction or Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)

A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects

Use of the LEVA® Pelvic Health System for Fecal Incontinence

The Role of Timed Awakening in Treatment of Enuresis

An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in the Home Setting for Incontinence in Adult Males

Measurements of Body Iron Excretion of Healthy Adults

A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers

Maintenance of Recommended Sodium Intake

Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics

Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients

A Crohn's Disease Diet to Reduce Symptoms of Crohn's Disease

Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects

Translating Unique Learning for Incontinence Prevention

Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

Firefighter Soot, Sauna, and Sweat Excretion Pilot Study